EUVIMEDEUVIMED entdecken
Crossref

Ethical Issues Related to the Use of GLP‐1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large

Francesca Minerva iD

Bioethics · 2026-06 · 40 (5) · 505-518

DOI: 10.1111/bioe.70068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioethics, online erschienen am 07.12.2025. Verfasst von Francesca Minerva. Beteiligte Einrichtung: University of Milan-Department of Philosophy, Milan, Italy. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Glucagon-Like Peptides, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 140 Literaturangaben. Gefördert von: University of Milan, Grant/Award Number: P20225A73K_003; Ministry of University and Research..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This paper explores the ethical implications of emerging weight‐loss medications such as Semaglutide (Ozempic) and Tirzepatide (Mounjaro), analysing their therapeutic applications for obesity and potential use as enhancement drugs. These medications promise significant benefits, including improved individual health outcomes, reduced healthcare costs and, potentially, reduced environmental harms. However, their widespread adoption raises various concerns, such as unknown long‐term side effects, the exacerbation of weight‐based discrimination, and the reinforcement of socioeconomic disparities. The paper argues that, with robust regulatory frameworks in place, the potential benefits of these medications are likely to outweigh the risks. Nonetheless, ongoing monitoring of their effect on individuals and society at large remains essential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesObesityAnti-Obesity AgentsHumansWeight LossTirzepatide

Stichwörter der Autor:innen

GLP‐1 receptor agonistsOzempicSemaglutideTirzepatidebody positivityclimate changefactory farmingfat studiesobesitytherapy vs. enhancement

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesAnti-Obesity AgentsTirzepatide

Autor:innen und Institutionen

  • University of Milan-Department of Philosophy, Milan, Italy.

ORCID-Profile: Francesca Minerva

Förderung

  • University of Milan, Grant/Award Number: P20225A73K_003; Ministry of University and Research.

Zitieren

APA

Minerva, F. (2026). Ethical Issues Related to the Use of GLP‐1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large. Bioethics, 40(5), 505-518. https://doi.org/10.1111/bioe.70068

Vancouver

Minerva F. Ethical Issues Related to the Use of GLP‐1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large. Bioethics. 2026;40(5):505-518. doi:10.1111/bioe.70068

BibTeX
@article{Minerva2026,
  author = {Minerva, Francesca},
  title = {Ethical Issues Related to the Use of GLP‐1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large},
  journal = {Bioethics},
  year = {2026},
  volume = {40},
  number = {5},
  pages = {505--518},
  doi = {10.1111/bioe.70068}
}
Kostenlos starten →